Back to Results

Catalyst Pharmaceuticals Inc (CPRX)

Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for people living with rare diseases in the United States. Its marketed products include Firdapse, used for patients with Lambert-Eaton myasthenic syndrome, Fycompa for focal onset seizures and tonic-clonic seizure, and AGAMREE for Duchenne muscular dystrophy. The company also has licensing arrangements with BioMarin Pharmaceutical Inc. and a collaboration and license agreement with Endo Ventures Limited related to the development and commercialization of generic Sabril tablets. Founded in 2002, Catalyst Pharmaceuticals is based in Coral Gables, Florida. Its common stock is listed on the NASDAQ exchange under the ticker CPRX.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-CPRX
—
—
—
—
—
—
—
—
—
—
—
August 12, 2026
17.4x
3.8x
6.5x
3.855 B
—
0.1%
94.4%
20.2
—
94.0%
Send a message
Valuation • Fair Value

Catalyst Pharmaceuticals Inc (NASDAQ-CPRX) Fair Value by Valuation Model

Compare the primary fair value estimate for Catalyst Pharmaceuticals Inc (NASDAQ-CPRX) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

Not available

Data is currently unavailable.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

$20.06

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

NM

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use this section to compare the primary fair value estimate for Catalyst Pharmaceuticals Inc (NASDAQ-CPRX) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Catalyst Pharmaceuticals Inc (NASDAQ-CPRX)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

597 M

Current operating scale indicator.

Revenue Forecast

632.2 M

Forward revenue estimate.

EBITDA

305.8 M

Current operating profitability reference.

EBITDA Forecast

311.2 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Catalyst Pharmaceuticals Inc (NASDAQ-CPRX) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Catalyst Pharmaceuticals Inc (NASDAQ-CPRX)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Not available

Data is currently unavailable.

Piotroski Score

7

Relatively strong quality score.

Beneish M-Score

-1.81

Intermediate zone that deserves monitoring.

Altman Z-Score

20.2

Relatively strong balance-sheet zone.

FCF / Net Income

94.0%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Catalyst Pharmaceuticals Inc (NASDAQ-CPRX). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Catalyst Pharmaceuticals Inc (NASDAQ-CPRX)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 12, 2026

Days to Earnings

22

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

Not available

Data is currently unavailable.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Catalyst Pharmaceuticals Inc (NASDAQ-CPRX), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Catalyst Pharmaceuticals Inc (NASDAQ-CPRX) Stock Forecast & Technical Outlook

Review Catalyst Pharmaceuticals Inc (NASDAQ-CPRX) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Catalyst Pharmaceuticals Inc (NASDAQ-CPRX) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Catalyst Pharmaceuticals Inc (NASDAQ-CPRX) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Catalyst Pharmaceuticals Inc (NASDAQ-CPRX) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Catalyst Pharmaceuticals Inc (NASDAQ-CPRX) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Catalyst Pharmaceuticals Inc (NASDAQ-CPRX) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Catalyst Pharmaceuticals Inc (NASDAQ-CPRX)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Not available

Analyst recommendation data for Catalyst Pharmaceuticals Inc (NASDAQ-CPRX) is not currently available.

Buy 0
Hold 0
Sell 0
FAQ • Fast Investor Answers

Catalyst Pharmaceuticals Inc (NASDAQ-CPRX) Stock FAQ

Quick answers about Catalyst Pharmaceuticals Inc (NASDAQ-CPRX) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
Not available
Data is currently unavailable
Valuation Rating
Not available
Classification is not available
Analyst Target
Not available
Data is currently unavailable
Financial Health
Not available
Data is currently unavailable

A fair value estimate for Catalyst Pharmaceuticals Inc (NASDAQ-CPRX) is not currently available in the latest data file.

A clear undervalued or overvalued classification is not currently available in the latest data file.

An analyst price target for Catalyst Pharmaceuticals Inc (NASDAQ-CPRX) is not currently available in the latest data file.

The next earnings date currently listed for Catalyst Pharmaceuticals Inc (NASDAQ-CPRX) is August 12, 2026.

Dividend details for Catalyst Pharmaceuticals Inc (NASDAQ-CPRX) are not currently available in the latest data file.

The current P/E ratio listed for Catalyst Pharmaceuticals Inc (NASDAQ-CPRX) is 17.4x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Catalyst Pharmaceuticals Inc is 3.855 B.

The ticker symbol for Catalyst Pharmaceuticals Inc is NASDAQ-CPRX, and the stock is listed on NASDAQ.

Catalyst Pharmaceuticals Inc (NASDAQ-CPRX) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Catalyst Pharmaceuticals Inc is 0.1%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Catalyst Pharmaceuticals Inc is 94.4%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks on NASDAQ View more

Amgen Inc (AMGN) Amgen Inc (AMGN)
Gilead Sciences Inc (GILD) Gilead Sciences Inc (GILD)
Vertex Pharmaceuticals Inc (VRTX) Vertex Pharmaceuticals Inc (VRTX)
Regeneron Pharmaceuticals Inc (REGN) Regeneron Pharmaceuticals Inc (REGN)
Argenx NV ADR (ARGX) Argenx NV ADR (ARGX)
Revolution Medicines Inc (RVMD) Revolution Medicines Inc (RVMD)
Natera Inc (NTRA) Natera Inc (NTRA)
Alnylam Pharmaceuticals Inc (ALNY) Alnylam Pharmaceuticals Inc (ALNY)
BeOne Medicines AG DRC (ONC) BeOne Medicines AG DRC (ONC)
Biogen Inc (BIIB) Biogen Inc (BIIB)
Roivant Sciences Ltd (ROIV) Roivant Sciences Ltd (ROIV)
Moderna Inc (MRNA) Moderna Inc (MRNA)
BioNTech SE (BNTX) BioNTech SE (BNTX)
Insmed Inc (INSM) Insmed Inc (INSM)
Incyte Corporation (INCY) Incyte Corporation (INCY)
United Therapeutics Corporation (UTHR) United Therapeutics Corporation (UTHR)
Neurocrine Biosciences Inc (NBIX) Neurocrine Biosciences Inc (NBIX)
Genmab AS (GMAB) Genmab AS (GMAB)
BridgeBio Pharma Inc (BBIO) BridgeBio Pharma Inc (BBIO)
Ascendis Pharma AS (ASND) Ascendis Pharma AS (ASND)
Exelixis Inc (EXEL) Exelixis Inc (EXEL)
Madrigal Pharmaceuticals Inc (MDGL) Madrigal Pharmaceuticals Inc (MDGL)
Abivax SA ADR (ABVX) Abivax SA ADR (ABVX)
Biomarin Pharmaceutical Inc (BMRN) Biomarin Pharmaceutical Inc (BMRN)